Latest Conference Coverage

Patient Feedback on Telehealth: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the positive feedback from patients when discussing telehealth. [WATCH TIME: 4 minutes]

Masupirdine Improves Agitation and Aggression in Alzheimer Disease

A phase 3 trial has been initiated to further study masupirdine’s effect on agitation in patients with Alzheimer dementia.

Future Integration, Coverage for Telemedicine in Multiple Sclerosis: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed the necessary data to support telemedicine’s integration into clinical care. [WATCH TIME: 4 minutes]

Lecanemab Reduces Amyloid in Patients With Early Alzheimer Disease

Data show a clinical benefit via a reduction in brain amyloid as early as 3 months in the open-label extension period.

Choosing Therapies for Patients With MS: Devon Conway, MD

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the process of choosing a therapy for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Tackling Multiple Sclerosis With Combination Treatment Approaches, Biomarkers: Jeffrey Cohen, MD

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the possibility of using multiple DMTs to combat the effects of MS. [WATCH TIME: 3 minutes]

Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD

The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]

Choosing Treatments for Patients With Multiple Sclerosis: Devon Conway, MD

Discussing newer treatment options in the MS field, the staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic noted that patient preference can play a part in the decision-making process. [WATCH TIME: 3 minutes]

New Medications for Multiple Sclerosis Treatment: Devon Conway, MD

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed emerging treatments in the MS field. [WATCH TIME: 2 minutes]

Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]

Low-Dose Lithium Shows Mixed Benefits for Alzheimer, Fails to Improve Behavioral Complications

Despite not being significantly superior to placebo on agitation and aggression, lithium showed a greater reduction in those with high Young Mania Rating Scale scores.

CMSC 2021: Top Interviews and Key Takeaways

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Evaluating Early Data on Focused Ultrasound for Patients With Alzheimer Disease

Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.

Applications of MRI-Guided FUS in Alzheimer Disease: Ali Rezai, MD

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University spoke on how technology can be used to open the blood-brain barrier in patients with AD. [WATCH TIME: 7 minutes]

Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology

The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.

UC San Diego Health: Institutional Perspectives in Neurology, Chaired by Jennifer Graves, MD, PhD, MAS

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

Investigating the Use of MRI-Guided Focused Ultrasound in Alzheimer Disease

Ali Rezai, MD, executive chair of the Rockefeller Neuroscience Institute at West Virginia University, provided an overview of FUS technology and its use in opening the blood-brain barrier.

AMX0035 Meets Primary Safety and Tolerability End Point in Alzheimer Disease

A higher incidence of gastrointestinal events was observed in the treatment group compared with placebo, similar to what was seen in clinical trials of AMX0035 in amyotrophic lateral sclerosis.

Therapeutic Approaches to Fatigue in Multiple Sclerosis: Anna Kratz, PhD

Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]

Anna Kratz, PhD, on Managing MS Fatigue in a Multifaceted Way

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.

Strategies, Tools for Treating Fatigue in Multiple Sclerosis: Anna Kratz, PhD

The associate professor of Physical Medicine & Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine discussed challenges when addressing fatigue, as well as the need to integrate digital tools for patients with MS. [WATCH TIME: 4 minutes]

Masupirdine Shows Beneficial Effect in Alzheimer Disease Psychosis

Over 26 weeks of treatment, masupirdine demonstrated a sustained and durable effect on outcomes such as cognition and dementia-related psychosis.

A Multidisciplinary Approach to Fatigue in Multiple Sclerosis: Anna Kratz, PhD

The associate professor of Physical Medicine & Rehabilitation and nonclinical research psychologist at University of Michigan Medicine discussed the complexities of fatigue as a symptom following her presentation at CMCS 2021.

Low-Dose Whole Brain Radiation Therapy Elicits Positive Results in Early Alzheimer Disease Dementia

A presentation at CTAD 2021 included data from 5 patients enrolled in a phase 2a trial to evaluate neurocognitive, imaging, and safety outcomes of the therapeutic approach in early AD dementia.

Patients With Dementia Willing to Restart Research Participation Interrupted by COVID-19

Findings presented at CTAD 2021 included data from surveyed participants with dementia and healthy volunteers about starting in-person or remote research.

Evaluating Ocrelizumab in the CHIMES Trial: Mitzi Joi Williams, MD

The founder and CEO of Joi Wellness Group Multiple Sclerosis Center described motivations behind the evaluation of ocrelizumab (Ocrevus; Genentech) in minority populations with multiple sclerosis.

National Alzheimer Disease Registry Announced to Collect Clinical Practice Data

The new registry will collect routine clinical practice data from the care of patients with Alzheimer disease who are taking an FDA-approved disease-modifying therapy.

Autologous Adipose Stem Cells Are Safe in Alzheimer Disease, Slightly Improve Cognitive Function

Despite the cohort only consisting of 3 patients with Alzheimer disease, autologous cellular therapy data highlighted the potential of the treatment’s results on cognitive assessments such as Montreal Cognitive Assessment.

Correlation Between Plasma Tau Reduction, Cognitive Function Linked to Aducanumab Treatment

The data, which suggest that a lessened decline in cognition and function was correlated with a reduction in plasma p-tau181 levels in those with Alzheimer disease treated with aducanumab (Aduhelm; Biogen), were presented at CTAD 2021.

Topline Data From LAURIET Study in Alzheimer Disease Confirm Prior Findings

Study of semorinemab in a larger mITT population confirmed statistically significant reduction in rate of cognitive decline in patients with Alzheimer disease, compared with placebo, but failed to achieve other end points.